Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington; Hugues de Lavallade; Katie J Doores; Amy O'Reilly; Jeffrey Seow; Carl Graham; Thomas Lechmere; Deepti Radia; Richard Dillon; Yogita Shanmugharaj; Andreas Espehana; Claire Woodley; Jamie Saunders; Natalia Curto-Garcia; Jennifer O'Sullivan; Kavita Raj; Shahram Kordasti; Michael H Malim; Claire N Harrison; Donal P McLornan

doi:10.1038/s41375-021-01300-7

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington, Hugues de Lavallade, Katie J Doores, Amy O'Reilly, Jeffrey Seow, Carl Graham, Thomas Lechmere, Deepti Radia, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O'Sullivan, Kavita Raj, Shahram Kordasti, Michael H Malim, Claire N Harrison, Donal P McLornan

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Original language	English
Pages (from-to)	3573-3577
Number of pages	5
Journal	Leukemia
Volume	35
Issue number	12
Early online date	22 May 2021
DOIs	https://doi.org/10.1038/s41375-021-01300-7
Publication status	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-021-01300-7

Cite this

Harrington, P., de Lavallade, H., Doores, K. J., O'Reilly, A., Seow, J., Graham, C., Lechmere, T., Radia, D., Dillon, R., Shanmugharaj, Y., Espehana, A., Woodley, C., Saunders, J., Curto-Garcia, N., O'Sullivan, J., Raj, K., Kordasti, S., Malim, M. H., Harrison, C. N., & McLornan, D. P. (2021). Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 35(12), 3573-3577. https://doi.org/10.1038/s41375-021-01300-7

@article{ae40aedd19454ecbaf8a3463bfb20bc1,

title = "Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms",

author = "Patrick Harrington and {de Lavallade}, Hugues and Doores, {Katie J} and Amy O'Reilly and Jeffrey Seow and Carl Graham and Thomas Lechmere and Deepti Radia and Richard Dillon and Yogita Shanmugharaj and Andreas Espehana and Claire Woodley and Jamie Saunders and Natalia Curto-Garcia and Jennifer O'Sullivan and Kavita Raj and Shahram Kordasti and Malim, {Michael H} and Harrison, {Claire N} and McLornan, {Donal P}",

note = "Funding Information: Funding King{\textquoteright}s Together Rapid COVID-19 Call awards to MHM, KJD; A Huo Family Foundation Award to MHM, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM; part of the EDCTP2 programme supported by the European Union (RIA2020EF-3008 COVAB) to KJD, MHM; MRC Genotype-to-Phenotype UK National Virology Consortium (MR/W005611/1) to MHM, KJD; Wellcome Trust Investigator Award 106223/Z/14/Z to MHM; CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to KJD; MPN Voice Grant to CH and DM. Funding Information: Conflict of interest PH reports research funding from Bristol Myers Squibb and speakers fees from Incyte. HdL has received research grants and honoraria from Incyte and honoraria from Novartis and Pfizer. CH has received speaker fees from Novartis, Jannsen, CTI, Celgene, Medscape and has served on the Advisory Board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron and Astra Zenica. DM has received speaker fees and advisory boards Novartis, Celgene and Jazz pharmaceuticals. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = dec,

doi = "10.1038/s41375-021-01300-7",

language = "English",

volume = "35",

pages = "3573--3577",

journal = "Leukemia",

issn = "1476-5551",

publisher = "Springer Nature [academic journals on nature.com]",

number = "12",

}

Harrington, P , de Lavallade, H , Doores, KJ, O'Reilly, A, Seow, J , Graham, C , Lechmere, T, Radia, D, Dillon, R, Shanmugharaj, Y, Espehana, A, Woodley, C, Saunders, J, Curto-Garcia, N, O'Sullivan, J, Raj, K, Kordasti, S , Malim, MH , Harrison, CN & McLornan, DP 2021, 'Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms', Leukemia, vol. 35, no. 12, pp. 3573-3577. https://doi.org/10.1038/s41375-021-01300-7

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. / Harrington, Patrick ; de Lavallade, Hugues ; Doores, Katie J et al.
In: Leukemia, Vol. 35, No. 12, 12.2021, p. 3573-3577.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

AU - Harrington, Patrick

AU - de Lavallade, Hugues

AU - Doores, Katie J

AU - O'Reilly, Amy

AU - Seow, Jeffrey

AU - Graham, Carl

AU - Lechmere, Thomas

AU - Radia, Deepti

AU - Dillon, Richard

AU - Shanmugharaj, Yogita

AU - Espehana, Andreas

AU - Woodley, Claire

AU - Saunders, Jamie

AU - Curto-Garcia, Natalia

AU - O'Sullivan, Jennifer

AU - Raj, Kavita

AU - Kordasti, Shahram

AU - Malim, Michael H

AU - Harrison, Claire N

AU - McLornan, Donal P

N1 - Funding Information: Funding King’s Together Rapid COVID-19 Call awards to MHM, KJD; A Huo Family Foundation Award to MHM, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM; part of the EDCTP2 programme supported by the European Union (RIA2020EF-3008 COVAB) to KJD, MHM; MRC Genotype-to-Phenotype UK National Virology Consortium (MR/W005611/1) to MHM, KJD; Wellcome Trust Investigator Award 106223/Z/14/Z to MHM; CG was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to KJD; MPN Voice Grant to CH and DM. Funding Information: Conflict of interest PH reports research funding from Bristol Myers Squibb and speakers fees from Incyte. HdL has received research grants and honoraria from Incyte and honoraria from Novartis and Pfizer. CH has received speaker fees from Novartis, Jannsen, CTI, Celgene, Medscape and has served on the Advisory Board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron and Astra Zenica. DM has received speaker fees and advisory boards Novartis, Celgene and Jazz pharmaceuticals. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85106303189&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01300-7

DO - 10.1038/s41375-021-01300-7

M3 - Article

C2 - 34023850

SN - 1476-5551

VL - 35

SP - 3573

EP - 3577

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

UN SDGs

Access to Document

Other files and links

Cite this